Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 45 for your search:
Cancer Type/Condition:
Non-Hodgkin lymphoma, child
Stage/Subtype:
stage IV childhood lymphoblastic lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
2.
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
NCI
Protocol IDs:
HLMCC-0402
, NCT00369564, ACCL 0731
3.
Biological Therapy in Treating Patients With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
4.
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
5.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
6.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
7.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
8.
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 74
Sponsor:
NCI
Protocol IDs:
080051
, 08-C-0051, NCT00923910
9.
Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-AAAA5571
, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
10.
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
PSCI-2003-232
, NCT00084695
11.
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
12.
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
45 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS043
, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
13.
Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2001LS058
, UMN-MT2001-10, NCT00303719
14.
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS036
, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
15.
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS048
, UMN-0508M72589, UMN-MT2004-24, NCT00345865
16.
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
2005-0054
, NCT00290498
17.
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
18.
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
CHNMC-06141
, 06141, NCT00589563
19.
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
ID02-230
, NCT00671658
20.
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 45 years
Sponsor:
NCI
Protocol IDs:
FHCRC-2010.00
, 6095, NCT00719888
21.
Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BMTGG-NSH-807
, NSH 807, NCT00787761
22.
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 70
Sponsor:
NCI, NHLBI
Protocol IDs:
606
, U01 HL069294, NCT00864227
23.
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 to 40
Sponsor:
Other
Protocol IDs:
2006-0375
, NCT00866749
24.
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P2 L-D AB
, NCT00917826
25.
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
0 to 65
Sponsor:
Other
Protocol IDs:
2009-0266
, NCT01010217
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
